EMA (EU)
EVENT
ACT EU webinar on draft guidance on the conduct of clinical trials during public health emergencies
Published: 4/8/2026Detected: 3/26/2026
Summary preview
Outlines expected practices for sponsors to maintain participant safety, trial continuity, and data integrity when clinical trials are disrupted by public health emergencies.
Get the full analysis, free
Create a free account to see the complete summary, key takeaways, and why this matters for your products, and to get alerts like this by email.
Create free accountinfectious_disease
clinical
#ACT EU
#draft guidance
#public health emergencies
#clinical trials
#sponsor responsibilities
Official Source Document Source Verified
Access the original document directly from EMA.
More from EMA (EU)
- Pharmacovigilance Risk Assessment Committee (PRAC): 23 - 26 November 202611/23/2026
- Seventeenth meeting of the industry stakeholder platform on the operation of the centralised procedure for human medicines11/20/2026
- EMA annual call with General Practitioner Organisations' representatives11/20/2026
- Digitalisation and artificial intelligence in pharmaceutical manufacturing: Quality Innovation Group (QIG) - Follow-up roundtable meeting11/18/2026
- Meeting of the Executive Steering Group on Shortages and Safety of Medicinal Products (MSSG) - November 202611/18/2026